Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dorzolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 18/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA3 | P07451 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dorzolamide SCHEMBL9914274 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL4525137 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL12453422 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL12874119 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL3306381 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL4455530 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL12223216 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL9914275 | 1.00 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL3314050 | 0.99 | CA2 (0.98) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL28388851 | 0.99 | CA2 (0.98) | CA2CA1CA12CA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11781 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| US-12630599-B2 | CA2 compositions and methods for tunable regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| WO-2026102187-A1 | ENGINEERED VIRUS-LIKE PARTICLES COMPRISING A BASE EDITOR FOR THE TREATMENT OF GLAUCOMA, AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-3973954-B1 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITIONS FOR OPHTHALMIC ADMINISTRATION | NTC S R L (IT) | 2026-04-22 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-1999000133-A1 | METHOD FOR OPTIMIZING RETINAL AND OPTIC NERVE HEALTH | MERCK & CO., INC. (US) | 1999-01-07 | — | — | WO | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| CN-1199336-A | Method to increase retinal blood flow | MERCK & CO INC (US) | 1998-11-18 | — | — | CN | claimed |
| US-5789435-A | Method to increase retinal and optical nerve head blood flow velocity in order to preserve sight | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 1998-08-04 | — | — | US | claimed |
| EP-0833632-A4 | — | — | 1998-05-20 | — | — | EP | claimed |
| EP-0833632-A1 | METHOD TO INCREASE RETINAL BLOOD FLOW | Advanced Research & Technology Institute (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1998000159-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| WO-1997030704-A2 | USE OF CARBONIC ANHYDRASE INHIBITORS FOR TREATING MACULAR EDEMA | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 1997-08-28 | — | — | WO | claimed |
| WO-1996037203-A1 | METHOD TO INCREASE RETINAL BLOOD FLOW | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1996-11-28 | — | — | WO | claimed |
| US-4797413-A | Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use | MERCK & CO., INC. (US) | 1989-01-10 | — | — | US | claimed |